M&A Deal Summary

Pfizer Acquires Wyeth

On October 15, 2009, Pfizer acquired life science company Wyeth for 68.0B USD

Acquisition Highlights
  • This is Pfizer’s 10th transaction in the Life Science sector.
  • This is Pfizer’s 2nd largest (disclosed) transaction.
  • This is Pfizer’s 11th transaction in the United States.
  • This is Pfizer’s 2nd transaction in Pennsylvania.

M&A Deal Summary

Date 2009-10-15
Target Wyeth
Sector Life Science
Buyer(s) Pfizer
Deal Type Merger
Deal Value 68.0B USD
Advisor(s) Morgan Stanley
Evercore Group
J.P. Morgan Securities (Financial)
Simpson Thacher & Bartlett (Legal)

Target

Wyeth

Collegeville, Pennsylvania, United States
website
Wyeth is a research-driven pharmaceutical and health care products company. It discovers, develops, manufactures and markets pharmaceuticals, vaccines, biotechnology products, nutritionals and non-prescription medicines. The Company’s major divisions include Wyeth Pharmaceuticals, Wyeth Consumer Healthcare and Fort Dodge Animal Health.

Search 192,611 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try For Free 7-Day Free Trial

Buyer(S) 1

Buyer

Pfizer

New York, New York, United States

website


Category Company
Founded 1849
Sector Life Science
Employees8,300
Revenue 58.5B USD (2023)
DESCRIPTION
Pfizer office in Lake Forest, Illinois.
Pfizer office in Lake Forest, Illinois.

Pfizer is a global pharmaceutical company that is involved in the discovery, development, manufacture, and marketing of a wide range of healthcare products, including medicines and vaccines. The company's portfolio includes treatments across a broad spectrum of areas such as oncology, cardiology, neurology, and infectious diseases, among others. Pfizer was founded in 1849 and is based in New York, New York.


DEAL STATS #
Overall 11 of 43
Sector (Life Science) 10 of 39
Type (Merger) 2 of 2
State (Pennsylvania) 2 of 2
Country (United States) 11 of 31
Year (2009) 1 of 2
Size (of disclosed) 2 of 21
PREVIOUS DEAL
DATE TARGET DEAL TYPE VALUE
2008-06-10 Encysive Pharmaceuticals

Houston, Texas, United States

Encysive Pharmaceuticals, Inc., a biopharmaceutical company whose product for the treatment of pulmonary arterial hypertension.

Buy $195M
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2009-11-01 ViiV Healthcare

Middlesex, United Kingdom

ViiV Healthcare is a global specialist HIV company.

Buy -